Long-Term Safety and Efficacy of BMS-986165 in Subjects with Psoriasis (IM011-075)
Phase 4
Completed
- Conditions
- Moderate-to-Severe Plaque Psoriasis
- Registration Number
- jRCT2080224973
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
-Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis -Women must not be pregnant, lactating, or breastfeeding
Exclusion Criteria
-Any disease or medical condition that the investigator feels that would make the patient unsuitable for this study. -To be eligible for the study, a participant must not have active signs or symptoms of tuberculosis (TB) as judged by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- open label, single arm
- Primary Outcome Measures
Name Time Method - Incidence of Adverse Events (AE) and Serious Adverse Events (SAE) [ Time Frame: 96 weeks ]
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
US
Location not specified
US